It is, according to the World Health Organization, one of the most important tools to overcome the epidemic on a global scale.
PrEP (pre-exposure prophylaxis), available in France since 2016, consists of permanently taking, before any risk taking, dual antiretroviral therapy which then avoids infection in the event of contact with HIV.
A French-Canadian study (Ipergay) had made it possible to quickly confirm its effectiveness, and the evaluation led to the establishment that PrEP was effective "on demand", that is to say before and during a period of taking specific risks.
Launched in the United States in 2012, it has prevented so many contaminations without adverse effects for patients that this approach is now recommended by the WHO.
Read also
HIV: PrEP generics are now authorized throughout Europe
This approach is even more effective if it can be offered to the majority of people who expose themselves to risks that they cannot or do not want to avoid.
Today, those who have access to it are first and foremost the people...
This article is for subscribers only.
You have 64% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login